Indeed, breast cancer patients with hypo-phosphorylated ERRα are more likely to respond to hormonal-blockade therapy and have a longer overall survival time than those with hyper-phosphorylated ERRα, which may be a direct consequence of TBK1-mediated ERRα phosphorylation [57]. Here, ESRRA is linked to breast cancer.